TP53 and neoplasm: The preclinical data from our current study further support the rationale from our prior preclinical work (Ghosh et al, 2022) to combine APR-246 with immunotherapy in cancer patients (Park et al, 2022) and extend the potential applicability of this combination to patients irrespective of their tumor’s Trp53 status.